Form 4: Nuvation Bio Chief Regulatory Officer Boosts Stake with Significant Share Purchase
Insider Transaction Report
Nuvation Bio Inc.'s Chief Regulatory Officer, Kerry Wentworth, has acquired 50,000 shares of Class A Common Stock through two open market purchases, signaling increased insider confidence.
Summary
- Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio Inc. (NUVB), purchased a total of 50,000 shares of the company's Class A Common Stock.
- The first transaction on June 16, 2025, involved the acquisition of 26,000 shares at a price of $1.79 per share.
- The second transaction, also on June 16, 2025, involved the acquisition of an additional 24,000 shares at a price of $1.80 per share.
- Following these transactions, Kerry Wentworth directly beneficially owns 50,000 shares of Nuvation Bio Inc. Class A Common Stock.
- The Form 4 filing was signed on June 18, 2025, by Stephen Dang, acting as Attorney-in-Fact for Kerry Wentworth, under a Power of Attorney dated March 23, 2025.
Sentiment
Score: 8
Explanation: The significant open market purchase of shares by a high-ranking officer (Chief Regulatory Officer) is a strong indicator of insider confidence in the company's future performance and valuation, which is generally a very positive signal for investors.
Positives
- A significant purchase of 50,000 shares by a high-ranking officer (Chief Regulatory Officer) indicates strong insider confidence in the company's future prospects.
- The direct acquisition of shares through open market purchases suggests a belief that the current stock price represents good value.
- Increased insider ownership aligns the interests of management more closely with those of shareholders.
Future Outlook
NA
Industry Context
Insider purchases, especially by senior officers, can be seen as a positive signal within the biotechnology and pharmaceutical industries, where company-specific developments often drive stock performance. It suggests that the officer believes in the company's pipeline or strategic direction.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Delegation of Authority | Kerry Wentworth, Chief Regulatory Officer, granted a Power of Attorney to Philippe Sauvage, Moses Makunje, and Stephen Dang of Nuvation Bio Inc. to prepare and file SEC reports (Forms ID, 13D, 13G, 3, 4, 5) on her behalf. | 2025-03-23 | This is a standard corporate governance practice to ensure timely and compliant SEC filings for insider transactions, streamlining the reporting process. |
Stakeholder Impact
- Shareholders: The insider purchase may instill greater confidence among existing and potential shareholders, potentially leading to increased buying interest and a positive impact on share price.
- Employees: May view the insider purchase as a sign of stability and positive outlook for the company.
Key Dates
| Date | Description |
|---|---|
| 2025-03-23 | Date of Power of Attorney granted by Kerry Wentworth. |
| 2025-06-16 | Date of two separate Class A Common Stock purchases by Kerry Wentworth. |
| 2025-06-18 | Date the Form 4 filing was signed. |
Recommendation
buyKeywords
Nuvation Bio Inc., NUVB, Insider Trading, Form 4, Share Purchase, Kerry Wentworth, Chief Regulatory Officer, Stock Acquisition, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.